Amgen

October 24, 2018
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam's Thirty Year Journey to First Approval

RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval

[vc_row][vc_column][vc_column_text]   In August 2018, the FDA & European Commission announced the approval of Alnylam Pharmaceutical’s ONPATTRO, a first-of-its-kind RNA interference (RNAi) therapeutic. Evolution Executive’s latest […]
June 4, 2018

The Future of BioManufacturing: In Silico Modelling

March 27, 2018

All Eyes on Oxford Nanopore after further £100m funding raised at £1.5B Valuation

[vc_row][vc_column][vc_column_text] Oxford Nanopore recently announced that it has attracted a further £100M in funding. The latest investment round values Oxford Nanopore at £1.5B, with Singapore-based GIC, […]
July 14, 2017

Looking Beyond Genomics: A Holistic Approach to Precision Medicine

[vc_row][vc_column][vc_column_text] England’s Chief Medical Officer, Dame Sally Davies, recently called for making genomic testing as common as blood tests in order to usher in the era […]
Contact Us